Overview

Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

Status:
Completed
Trial end date:
2021-06-10
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, study of TGR-1202, a PI3K delta inhibitor, administered as a single agent in Chronic Lymphocytic Leukemia (CLL) patients who are intolerant to prior BTK inhibitors (ibrutinib, other) or prior PI3K delta inhibitors (idelalisib, other)
Phase:
Phase 2
Details
Lead Sponsor:
TG Therapeutics, Inc.